E2F5 Antibody

What is E2F5 and what cellular processes is it involved in?

E2F5 is a member of the E2F family of transcription factors that plays a critical role in cell cycle regulation, particularly in controlling the G1/S transition. Research has shown that E2F5 is involved in cell proliferation and may contribute to oncogenesis when overexpressed. As part of the E2F family, it binds to specific DNA sequences and regulates gene expression related to cell cycle progression . E2F5 has been found to have predominantly cytoplasmic expression in cancer cells, which differentiates it from normal and benign tissues where expression is typically absent or minimal .

What types of E2F5 antibodies are available for research purposes and how do they differ?

E2F5 antibodies are available as polyclonal and monoclonal variants, each with specific advantages. Polyclonal antibodies, such as rabbit polyclonal anti-E2F5, recognize multiple epitopes on the E2F5 protein, making them highly sensitive for detection in various applications . These antibodies typically display reactivity across multiple species including human, mouse, and rat samples . For experimental applications, researchers should consider the specific immunogen sequence used to generate the antibody and verify that it targets the region of interest in the E2F5 protein (UniProt: Q15329) .

How should E2F5 antibody be stored and handled to maintain optimal activity?

For optimal preservation of E2F5 antibody activity, storage at -20°C is recommended for long-term maintenance, with working aliquots kept at 4°C for short-term use. Repeated freeze-thaw cycles should be avoided as they can lead to antibody degradation and reduced activity. When handling the antibody, it's important to maintain sterile conditions and use appropriate buffers based on the intended application. For immunohistochemistry applications, proper antibody dilution and epitope retrieval methods (such as heat-induced epitope retrieval in pH9 buffer) are crucial for successful detection of E2F5 .

What are the validated applications for E2F5 antibody in cancer research?

E2F5 antibodies have been validated for several experimental applications in cancer research, primarily Western blotting (WB) and immunohistochemistry (IHC) . In ovarian epithelial cancer studies, E2F5 antibody has been optimized for immunohistochemistry on tissue microarrays (TMAs) and full sections of formalin-fixed, paraffin-embedded tissues . For hepatocellular carcinoma research, E2F5 antibody has been effectively used in Western blotting to evaluate expression levels and confirm siRNA knockdown efficiency . The cytoplasmic staining pattern observed with E2F5 antibody provides a distinct advantage for distinguishing malignant tissue from normal and benign samples in diagnostic applications .

What is the recommended protocol for immunohistochemistry using E2F5 antibody?

For immunohistochemistry with E2F5 antibody, the following protocol has shown optimal results:

• Prepare tissue sections (4-μm) from formalin-fixed, paraffin-embedded samples

• Perform heat-induced epitope retrieval by microwaving in DAKO Target Retrieval Solution at pH9 for 20 minutes

• Block endogenous peroxidase activity and non-specific binding sites

• Apply optimized dilution of E2F5 antibody and incubate (dilution should be determined experimentally)

• Visualize using appropriate detection system

• Counterstain, dehydrate, and mount

The expression of E2F5 antibody is primarily cytoplasmic, and positive staining is indicated by any detectable cytoplasmic staining in the lesional cells of interest . Control samples should include normal epidermis as a positive control (which shows staining in basal and granular layers) and normal ovary as a negative control .

How can E2F5 antibody be used effectively in Western blotting experiments?

For Western blotting applications using E2F5 antibody:

• Prepare protein lysates from cells/tissues of interest

• Determine protein concentration and load equal amounts per lane (typically 20-50 μg)

• Separate proteins by SDS-PAGE (10-12% gel is suitable for detecting E2F5's 37 kDa molecular weight)

• Transfer proteins to PVDF or nitrocellulose membrane

• Block with appropriate blocking buffer

• Incubate with optimized dilution of E2F5 antibody

• Wash and apply HRP-conjugated secondary antibody

• Develop using enhanced chemiluminescence

This protocol has been validated for detecting E2F5 protein expression and confirming knockdown efficiency in experiments using E2F5-specific siRNA in hepatocellular carcinoma cell lines . When assessing knockdown efficiency, it's recommended to perform both qRT-PCR and Western blotting to confirm repression at both RNA and protein levels .

How does E2F5 expression correlate with cancer development and progression?

E2F5 overexpression has been documented in various human cancers, including ovarian epithelial cancer and hepatocellular carcinoma . In hepatocellular carcinoma, E2F5 was significantly overexpressed in primary HCCs compared with normal liver tissues (p = 0.008) . Similarly, in ovarian epithelial cancer, E2F5 expression was detected in cancer samples but not in normal and benign tissues . This differential expression pattern suggests E2F5 may serve as a potential biomarker for malignancy and could play a role in cancer development and progression. Functional studies using E2F5 knockdown have demonstrated reduced cell proliferation, colony formation, and migration capabilities in cancer cells, supporting a potential oncogenic role for E2F5 .

How can E2F5 antibody be used to improve cancer diagnostics?

E2F5 antibody has shown promising potential as a diagnostic tool, particularly in combination with established biomarkers. In ovarian epithelial cancer, combining E2F5 status with CA125 (a conventional OEC biomarker) significantly improves diagnostic accuracy . The presence of either CA125 or E2F5 increases sensitivity of OEC detection to 97.9% (compared to 87.5% with CA125 alone), while the presence of both markers increases specificity to 72.5% (from 55% with CA125 alone) .

What experimental approaches can be used to study the functional role of E2F5 in cancer cells?

To investigate the functional role of E2F5 in cancer cells, several experimental approaches have been validated:

• RNA interference (RNAi): Using E2F5-specific siRNA to knock down expression and assess effects on cellular phenotypes. This approach revealed that E2F5 knockdown significantly reduces:

  • Cell proliferation (p = 0.004)

  • Colony formation capacity (p = 0.004)

  • Anchorage-independent growth in soft agar assays (p = 0.009)

  • Cell migration and invasion capabilities (p = 0.021)

• Cell cycle analysis: Flow cytometry after E2F5 knockdown showed accumulation of G0/G1 phase cells (76.5% vs. 71.7% in control) and reduction of S phase cells (5.2% vs. 11.9% in control), suggesting E2F5's role in G1/S transition

• Tissue microarray (TMA) analysis: Using E2F5 antibody on TMAs containing normal, benign, and malignant tissues to assess expression patterns and correlate with clinicopathological features

These methodological approaches provide complementary data on E2F5's role in cancer development and progression, establishing its potential as both a biomarker and therapeutic target.

What are common issues with E2F5 antibody staining and how can they be resolved?

Common challenges with E2F5 antibody staining include:

• Weak or no staining: E2F5 expression may not be very strong even in positive samples . To resolve this:

  • Optimize antigen retrieval methods (heat-induced epitope retrieval in pH9 buffer has shown success)

  • Adjust antibody concentration and incubation time

  • Ensure proper storage of antibody to maintain activity

  • Use amplification systems for signal enhancement

• Background staining: To reduce non-specific binding:

  • Optimize blocking conditions (duration, buffer composition)

  • Ensure proper washing between steps

  • Titrate primary and secondary antibodies

  • Include appropriate negative controls (e.g., normal ovary tissue has shown no background staining)

• Inconsistent results: For improved reproducibility:

  • Standardize tissue processing (fixation time, processing protocols)

  • Use positive controls (normal epidermis shows staining in basal and granular layers)

  • Consider double-punching samples in tissue microarrays to account for tumor heterogeneity

How can researchers quantify E2F5 expression levels accurately?

For accurate quantification of E2F5 expression:

• Western blot quantification:

  • Use housekeeping proteins (β-actin, GAPDH) as loading controls

  • Apply densitometry analysis with appropriate software (ImageJ, Image Lab)

  • Include a standard curve of recombinant protein for absolute quantification

  • Normalize E2F5 signal to loading control

• Immunohistochemistry scoring:

  • Implement standardized scoring systems (presence/absence of cytoplasmic staining has been effective)

  • Use digital pathology tools for objective quantification

  • Consider multiple independent observers to confirm results (100% concordance between observers has been reported)

  • Account for tumor heterogeneity by examining multiple areas

• qRT-PCR for mRNA quantification:

  • Use validated reference genes for normalization

  • Apply the comparative CT (ΔΔCT) method

  • Include technical replicates and biological replicates

What are the advanced approaches for studying E2F5 protein interactions and modifications?

Advanced techniques for studying E2F5 protein interactions and modifications include:

• Co-immunoprecipitation (Co-IP): Using E2F5 antibody to pull down protein complexes and identify interacting partners through mass spectrometry or Western blotting. This approach can reveal novel binding partners beyond the known p130 interaction.

• Chromatin Immunoprecipitation (ChIP): E2F5 antibody can be used to identify genomic binding sites of E2F5, illuminating its direct transcriptional targets. This technique provides insight into the gene networks regulated by E2F5 in normal and cancer cells.

• Post-translational modification (PTM) analysis: E2F5 undergoes multiple PTMs including phosphorylation (e.g., at S54) and ubiquitination (e.g., at K53, K61, K70) . Mass spectrometry following immunoprecipitation with E2F5 antibody can identify novel modifications and their regulatory roles.

• Proximity ligation assay (PLA): Combining E2F5 antibody with antibodies against suspected interacting proteins to visualize and quantify protein-protein interactions in situ within cells and tissues.

How should researchers interpret E2F5 staining patterns in different tissue types?

When interpreting E2F5 staining patterns across tissue types:

How can E2F5 expression data be integrated with other molecular markers for improved cancer classification?

Integration of E2F5 expression data with other molecular markers can enhance cancer classification:

• Multimarker panels: Combining E2F5 with established biomarkers (like CA125 for ovarian cancer) significantly improves diagnostic accuracy. The combined use of E2F5 and CA125 increases both sensitivity (to 97.9%) and specificity (to 72.5%) compared to CA125 alone .

• Machine learning approaches:

  • Training machine learning systems with multiple features including E2F5 status can achieve high accuracy in distinguishing malignant from benign cases

  • A 13-feature system including E2F5 status achieved impressive metrics: sensitivity (97.92%), specificity (97.37%), and accuracy (97.67%)

  • Exclusion of E2F5 status from the model reduced performance, highlighting its independent predictive value

• Data integration strategies:

  • Combine protein expression (from IHC) with genetic and transcriptomic data

  • Correlate E2F5 status with clinical parameters (stage, grade, outcome)

  • Consider pathway-level analysis incorporating other cell cycle regulators

What statistical approaches are recommended for analyzing E2F5 expression in cancer research?

For robust statistical analysis of E2F5 expression data in cancer research:

Table 1: Comparison of Diagnostic Performance with and without E2F5 Status

Data derived from studies of ovarian epithelial cancer diagnosis

What are promising areas for future research using E2F5 antibody?

Future research directions utilizing E2F5 antibody include:

• Expanded cancer type profiling: While E2F5 overexpression has been documented in ovarian and liver cancers , systematic profiling across a wider range of cancer types could reveal additional diagnostic applications. Multi-cancer tissue microarrays with E2F5 antibody staining would efficiently address this question.

• Single-cell analysis: Applying E2F5 antibody in single-cell protein profiling techniques could reveal intratumoral heterogeneity and identify specific cell populations with differential E2F5 expression, potentially identifying treatment-resistant subpopulations.

• Liquid biopsy development: Investigation of E2F5 protein or autoantibodies in patient serum as potential non-invasive biomarkers, expanding on the promising tissue-based diagnostic results .

• Therapeutic targeting: Using E2F5 antibody to evaluate the efficacy of emerging therapeutics designed to modulate E2F5 expression or activity, particularly given its role in cell proliferation and migration .

How might E2F5 research contribute to personalized medicine approaches?

E2F5 research has several potential applications in personalized medicine:

• Molecular stratification: E2F5 expression patterns could help stratify patients into molecular subgroups with different prognoses or treatment responses. E2F5 status, in combination with other molecular markers, has already shown impressive classification accuracy (97.67%) .

• Treatment selection biomarker: Given E2F5's role in cell cycle regulation and its effect on G1/S transition , its expression status could potentially predict response to cell cycle-targeting therapies or CDK inhibitors.

• Monitoring response: Serial measurement of E2F5 expression using antibody-based methods could provide real-time monitoring of treatment efficacy or disease recurrence.

• Combination therapies: Understanding E2F5's interaction network could reveal synergistic therapeutic combinations, with antibody-based assays providing crucial biomarker data to guide treatment selection.